Akero’s treatment for NASH falls short in cirrhosis study; A Q&A with the global head of Boehringer Ingelheim’s innovation unit

Taking stock of the drug industry, from the lab to the medicine chest

October 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Akero's treatment for NASH falls short in cirrhosis study Akero said the study's primary goal of improving liver fibrosis, or scarring, was not achieved. By Adam Feuerstein STAT+ | A Q&A with the global head of Boehringer Ingelheim's innovation unit At an event in London last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.  By Andrew Joseph Opinion: Connecticut's comptroller explains his thinking about GLP-1s for state employees Connecticut's comptroller explains his office's innovative approach to covering weight loss drugs like Ozempic and Wegovy. By Sean Scanlon Adobe STAT+ | Sana to lay off nearly a third of staff, de-prioritize a key program Sana Biotechnology, a startup that just a couple years ago raised over $1 billion, will lay off employees and delay a key program. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser